“If you are making $3 billion a year on Gleevec [a cancer therapy], could you get by with $2 billion?” Dr. [Brian] Druker, who is now director of the Knight Cancer Institute at Oregon Health and Science University, said in an interview.
A group of cancer researchers and physicians calls for reductions in some drug prices.
Here’s another good one:
Dr. John M. Goldman, emeritus professor of hematology at Imperial College in London and a co-author of the commentary, said he knew several researchers who declined to become authors because they feared losing research money from the industry.
Dr. Kantarjian, the lead author, said that was a risk.
“I am sure I am going to be blackballed,” he said. “My research career will be hurt.”
But he said it was time to speak out. “Pharmaceutical companies have lost their moral sense,” he said.